IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren
A phase 2 trial of IN10018, Pegylated liposomal doxorubicin in ovarian cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.
Overview
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT06014528 by InxMed (Shanghai) Co., Ltd., with 168 participants planned, started 2022-09-06 and due to reach its primary completion in 2026-12-24. Interventions recorded: IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin. Conditions listed: Ovarian Cancer Recurrent. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialIN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
Shares InxMed (Shanghai), IN10018, Ovarian cancer.
- TrialA Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Shares InxMed (Shanghai), IN10018.
- TrialIN10018 Combination Therapy in Treatment-naïve ES-SCLC
Shares InxMed (Shanghai), IN10018.
- CompanyInxMed
Shares IN10018, Ovarian cancer.
- TrialA Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- TrialOncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b)
- TrialMirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
- TrialA Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)